Conditions: Schizophrenia
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 196
Healthy volunteers: no

Brief summary:
This is an extension study of A7501013 (P05771/NCT00145496) to further test

the efficacy and safety of Asenapine compared with a

marketed agent (olanzapine) in the treatment of patients with

persistent negative symptoms of schizophrenia.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: asenapine intervention 2: olanzapine
Intervention descriptions: intervention 1: 5-10 mg sublingually twice daily for 26 weeks intervention 2: 5-20 mg by mouth once daily for 26 weeks

Protocol document: